Sale of Basilea’s novel PARG inhibitor discovery programUpfront and milestone payments of up to CHF 242 million and approximately 5% participation in net.
SEATTLE, Oct. 20, 2021 (GLOBE NEWSWIRE) According to Coherent Market Insights, the global charcot-marie-tooth disease market is estimated to be valued.